Oligometastatic Disease and SBRT — Board Review Summary

PART I — DEFINITIONS, TAXONOMY, AND PATIENT SELECTION

The Modern Definition

Oligometastatic disease is not simply "5 or fewer metastases." The ESTRO-ASTRO consensus framing is more useful: a patient has a limited metastatic burden where all known sites can potentially be treated safely with definitive-intent local therapy.
The board-style caution is just as important: ability to treat everything does not mean one should treat everything.

Taxonomy to Know

StateDefinitionPractical implication
Synchronous oligometastaticLimited metastatic disease present at initial diagnosisOften more aggressive biology; treatment benefit varies strongly by histology and systemic therapy context
Metachronous oligorecurrenceLimited metastases after a disease-free intervalUsually more favorable than synchronous disease, especially with long interval and controlled primary
Repeat oligometastaticNew limited metastases after prior successful MDTCan be considered for repeat MDT if disease kinetics remain indolent
Induced oligometastaticPreviously polymetastatic disease becomes limited after systemic responseTechnically treatable, but biology may be less favorable than de novo limited disease
OligopersistentResidual active sites after otherwise effective systemic therapyGoal is consolidation of resistant/residual disease
OligoprogressiveA small number of sites progress while other disease remains controlled on systemic therapyGoal is usually to delay systemic therapy switch, not to cure disseminated disease

Selection Framework

Favors MDT / SBRTUse caution
Good performance status; controlled primary; limited number and volume of lesions; metachronous disease; long disease-free interval; slow kinetics; histology with known MDT signal; safe OAR geometry; meaningful systemic options remainRapid polymetastatic biology; many prior lines with short responses; uncontrolled primary; lesions abutting serial OARs; active systemic toxicity; widespread occult-risk biology; treating all sites would require unsafe compromise
Board pearl: selection is moving beyond lesion count toward biology, disease kinetics, imaging sensitivity, systemic therapy context, and patient goals. The safest exam answer is not "SBRT all oligomets"; it is "selective MDT in the right clinical state."

PART II — CLASSIC OLIGOMETASTATIC MDT TRIALS

Positive Early Signal Trials

TrialPopulationInterventionMain result
Iyengar NSCLC phase IINSCLC, limited metastases after induction systemic therapyConsolidative RT to primary/metastases + maintenance systemic therapyImproved PFS; helped establish the NSCLC consolidative-therapy hypothesis
GomezStage IV NSCLC, no progression after systemic therapy, ≤3 metastasesLCT by SBRT, surgery, or other local therapy vs maintenance / observationMedian PFS 14.2 vs 4.4 mo; median OS 41.2 vs 17 mo
SABR-COMETMixed histologies, controlled primary, 1-5 metastasesSABR to all sites + SOC vs SOC5y OS 42.3% vs 17.7%; practice-shaping but phase II and histology-mixed
ORIOLEOligorecurrent hormone-sensitive prostate cancer, ≤3 metastasesSABR vs observationProgression at 6 mo lower with SABR; total consolidation of PSMA-avid disease mattered
SINDASEGFR-mutant synchronous oligometastatic NSCLC, ≤5 metastasesTKI +/- upfront SBRT to all diseaseImproved PFS and OS; important molecularly selected positive trial
SABR-COMET interpretation: it is the landmark mixed-histology randomized trial and supports the oligometastatic paradigm, but it also reminds us that ablative MDT can cause rare severe toxicity. It should not be used as a blanket justification for treating every limited-metastatic presentation.

Modern Cautionary Trials

TrialPopulationResultBoard takeaway
NRG-BR002Breast cancer, newly metastatic or limited progression, 1-4 metastasesNo PFS benefit from adding ablation to systemic therapy; phase III portion did not proceedDo not assume breast oligomets behave like prostate or selected NSCLC
NRG-LU002NSCLC, ≤3 extracranial metastatic sites, stable after 4 cycles first-line systemic therapy; 90% received IO-based therapyPFS HR about 0.93 overall and 0.90 in IO-treated pts; no OS benefit; more grade 3+ pneumonitis with LCTIn the modern IO era, routine LCT for all limited-metastatic NSCLC is not supported
SABR-5Mixed histologies, up to 5 metastasesProspective safety data: grade 3 toxicity about 4%, grade 5 rareUseful for safety counseling, not a randomized efficacy proof
2026 synthesis: MDT is real, but the field has matured from "oligomets are curable" to "some oligometastatic states are locally actionable, and some patients benefit." Histology, systemic therapy era, imaging, and kinetics are doing a lot of the work.

PART III — OLIGOPROGRESSION

Conceptual Difference from Oligometastatic Disease

In oligoprogression, most disease remains controlled on systemic therapy, while a limited number of resistant clones progress. The most common treatment goal is to ablate resistant sites and extend time on the current systemic therapy.

Key Oligoprogression Trials

TrialPopulationInterventionMain result / takeaway
CURBMetastatic NSCLC and breast cancer, 1-5 progressive lesions, no upper limit on stable lesionsSBRT to progressive sites + SOC vs SOCMedian PFS 7.2 vs 3.2 mo; benefit driven by NSCLC, not breast
HALTNSCLC progressing on targeted therapySBRT while continuing TKI strategySupports the TKI-era logic of controlling resistant deposits, but context matters
STOPMixed oligoprogressive cancersSBRT vs standard systemic managementNo clear PFS benefit overall; reinforces need for histology-specific selection
SUPPRESSNSCLC on IO or TKI with oligoprogressionSBRT strategyDesigned to test whether local ablation can delay systemic escalation
CURB2 / COMET-10Ongoing / newer generation OPD strategiesProtocolized SBRT, commonly with 10 Gy x 3 default dosing for many lesionsMoving toward cleaner endpoints, PROs, cost-effectiveness, and biomarkers

Disease-Site Nuance

  • NSCLC: the strongest oligoprogressive signal is in selected patients, especially where SBRT can defer systemic therapy change.
  • Prostate: MDT is increasingly used to defer ADT or delay systemic escalation in oligorecurrent / oligoprogressive settings.
  • Breast: randomized data have been sobering; breast MDT should be selective and goal-driven rather than automatic.
  • RCC: favorable or intermediate-risk, metachronous, good-KPS patients can be compelling MDT candidates, especially to defer systemic therapy.
  • Pancreas: EXTEND supports a PFS signal for chemo + MDT in very selected oligometastatic disease, but this is not a broad standard.

PART IV — PRACTICAL SBRT DELIVERY

Dose Principles

SBRT dose should be high enough for durable local control, but OAR constraints win. When lesions abut serial organs such as central airway, esophagus, bowel, spinal cord, or brachial plexus, dose de-escalation, more fractions, or not treating may be the right answer.

Common Dose Paradigms

SettingDose examplesComment
Generic OPD protocol default10 Gy x 3Used as a practical default in newer oligoprogression protocols when anatomy allows
Non-spine bone metastasis10 Gy x 3Typical ablative palliative/MDT schedule; contour GTV with modest bone-respecting CTV expansion
Peripheral lung metastasis18 Gy x 3High-BED option if chest wall and lung constraints permit
Central lung lesion10-12 Gy x 5Avoid 3-fraction treatment near proximal bronchial tree
Ultra-central lung lesion7.5 Gy x 8Use thoracic SBRT constraints and caution; not every lesion is a good SBRT target
Spine metastasis24 Gy x 1, 27 Gy x 3, or 30 Gy x 5Choice depends on cord/thecal sac constraints, epidural disease, stability, and prior RT
Liver / adrenal metastasis45-60 Gy / 3-5 fxMotion management and luminal GI constraints are often limiting

Technical Checklist

  • Image well: use disease-appropriate staging such as PSMA PET for prostate, FDG PET when relevant, MRI for liver/brain/spine, and high-quality chest imaging for lung.
  • Account for motion: 4DCT, breath-hold, gating, abdominal compression, or tracking depending on site.
  • Coordinate systemic therapy: consider washout windows and overlapping risks with VEGF inhibitors, TKIs, immunotherapy, and cytotoxic chemotherapy.
  • Respect prior RT: cumulative dose and future salvage options matter, especially for spine, central thorax, bowel, and pelvis.
  • Choose endpoints honestly: possible goals include local control, symptom prevention, systemic-therapy delay, avoiding a morbid event, or rarely durable remission.

PART V — HOW TO ANSWER BOARD-STYLE CASES

Decision Variables

VariableWhy it matters
Histology / molecular subtypeProstate, selected NSCLC, and RCC often behave differently than breast or pancreas
TimingMetachronous disease after a long interval is more favorable than synchronous widespread-risk disease
Disease kineticsSlow-growing disease is more likely to benefit from MDT than rapidly recurring polymetastatic disease
Systemic therapy contextModern IO and ARPI eras have changed the incremental value of LCT
Toxicity riskCentral thorax, bowel-adjacent, and reirradiation cases can erase the therapeutic ratio
Patient goalSymptom prevention, treatment-free interval, or disease control may matter more than theoretical cure
One-sentence exam answer: SBRT is appropriate for carefully selected oligometastatic or oligoprogressive patients when all active disease can be safely treated, the biology is favorable, systemic therapy context supports MDT, and the treatment goal is explicit.

CROSS-CUTTING HIGH-YIELD POINTS

  • Oligometastatic disease is a clinical state, not just a lesion count.
  • ESTRO-ASTRO: maximum metastasis number is determined by whether curative-intent local therapy can be safely delivered to all sites.
  • Treatable does not equal should treat.
  • Gomez and SABR-COMET are the classic positive trials supporting MDT.
  • ORIOLE/STOMP-style prostate data support MDT to delay progression and systemic therapy.
  • SINDAS is the memorable EGFR-mutant NSCLC positive trial.
  • NRG-BR002 is the key cautionary breast cancer trial.
  • NRG-LU002 is the modern IO-era cautionary NSCLC trial; routine LCT did not improve PFS or OS and increased pneumonitis.
  • CURB supports SBRT in oligoprogressive NSCLC, but not breast.
  • STOP reinforces that mixed-histology oligoprogression cannot be treated as one disease.
  • Common OPD dose: 10 Gy x 3, but anatomy and OAR constraints determine the real prescription.
  • SBRT near serial OARs should be fractionated, compromised, or avoided when constraints cannot be met.
  • Future direction: biomarker-selected MDT, better imaging, ctDNA/CTCs, and disease-specific randomized trials.

KEY LANDMARK TRIALS (memorize)

TrialDisease / settingOne-line takeaway
GomezOligometastatic NSCLC after systemic therapyLCT improved PFS and OS in selected pts with ≤3 metastases
SABR-COMETMixed oligometastatic cancersSABR improved long-term OS but with phase II and toxicity caveats
ORIOLEOligorecurrent prostate cancerSABR lowered early progression; untreated PSMA-avid disease predicted failure
STOMPOligorecurrent prostate cancerMDT delayed ADT initiation
SINDASEGFR-mutant oligometastatic NSCLCTKI + SBRT improved PFS and OS
NRG-BR002Oligometastatic breast cancerAdding ablation did not improve PFS; breast MDT should be selective
NRG-LU002Modern limited-metastatic NSCLCLCT after IO-era systemic therapy did not improve PFS/OS and increased pneumonitis
CURBOligoprogressive NSCLC / breastPFS benefit driven by NSCLC; no clear breast benefit
STOPMixed oligoprogressive cancersNo overall PFS benefit; histology-specific selection matters
EXTENDOligometastatic pancreasChemo + MDT improved PFS in highly selected disease
SABR-5Mixed oligometastatic cancersLarge prospective safety benchmark for treating up to 5 metastases